- Price
- $8.91
- Day
- -1.00%
- Mkt Cap
- $58.58M
- 52W Range
- $6.47 – $12.74
- Volume
- 10.0K
- Beta
- -0.12
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that, effective September 1, 2026, the company granted non-qualified stock options to purchase 19,865 shares of its common stock to two new employees under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.
Read full article